Secreted Wnt antagonists in leukemia: A road yet to be paved

Pehlivan M., Caliskan C., Yüce Z., Sercan H. O.

LEUKEMIA RESEARCH, cilt.69, ss.24-30, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 69
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.leukres.2018.03.011
  • Dergi Adı: LEUKEMIA RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.24-30
  • Anahtar Kelimeler: Wnt signaling pathway, Secreted Wnt antagonists, CML
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Wnt signaling has been a topic of research for many years for its diverse and fundamental functions in physiological (such as embryogenesis, organogenesis, proliferation, tissue repair and cellular differentiation) and pathological (carcinogenesis, congenital/genetic diseases, and tissue degeneration) processes. Wnt signaling pathway aberrations are associated with both solid tumors and hematological malignancies. Unregulated Wnt signaling observed in malignancies may be due to a wide spectrum of abnormalities, from mutations in the genes of key players to epigenetic modifications of Wnt antagonists. Of these, Wnt antagonists are gaining significant attention for their potential of being targets for treatment and inhibition of Wnt signaling. In this review, we discuss and summarize the significance of Wnt signaling antagonists in the pathogenesis and treatment of hematological malignancies.